Journal of vascular and interventional radiology : JVIR · 2023
Transjugular Intrahepatic Portosystemic Shunts in Pediatric Portal Hypertension: A Systematic Review and Meta-Analysis.
МетаанализСистематический обзорСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hermie Laurens, Van Cauwenberghe Lien, Dhondt Elisabeth, De Bruyne Ruth, Defreyne Luc
Аннотация
PURPOSE: To investigate the technical outcome, clinical outcome, and patency of transjugular intrahepatic portosystemic shunt (TIPS) in pediatric portal hypertension (PHT).
METHODS: A systematic search of MEDLINE/PubMed, EMBASE, Cochrane databases, ClinicalTrials.gov, and WHO ICTRP registries was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. An a priori protocol was registered at the PROSPERO database. Original full-text articles on pediatric patients (sample size of ≥5 patients with upper age limit of 21 years) with PHT who underwent TIPS creation for any indication were included.
RESULTS: Seventeen studies with 284 patients (average-weighted age of 10.1 years) were included, with an average-weighted follow-up of 3.6 years. TIPS was technically successful in 93.3% (95% confidence interval [CI], 88.5%-97.1%) of patients, with a major adverse event rate of 3.2% (95% CI, 0.7-6.9) and adjusted hepatic encephalopathy rate of 2.9% (95% CI, 0.6-6.3). The pooled 2-year primary and secondary patency rates were 61.8% (95% CI, 50.0-72.4) and 99.8% (95% CI, 96.2%-100.0%), respectively. Stent type (P = .002) and age (P = .04) were identified as a significant source of heterogeneity for clinical success. In subgroup analysis, the clinical success rate was 85.9% (95% CI, 77.8-91.4) in studies with a majority of covered stents, and 87.6% (95% CI, 74.1-94.6) in studies with a median age of 12 years or older.
CONCLUSIONS: This systematic review and meta-analysis demonstrates that a TIPS is a feasible and safe treatment for pediatric PHT. To improve clinical outcome and patency on the long term, the use of covered stents should be encouraged.
METHODS: A systematic search of MEDLINE/PubMed, EMBASE, Cochrane databases, ClinicalTrials.gov, and WHO ICTRP registries was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. An a priori protocol was registered at the PROSPERO database. Original full-text articles on pediatric patients (sample size of ≥5 patients with upper age limit of 21 years) with PHT who underwent TIPS creation for any indication were included.
RESULTS: Seventeen studies with 284 patients (average-weighted age of 10.1 years) were included, with an average-weighted follow-up of 3.6 years. TIPS was technically successful in 93.3% (95% confidence interval [CI], 88.5%-97.1%) of patients, with a major adverse event rate of 3.2% (95% CI, 0.7-6.9) and adjusted hepatic encephalopathy rate of 2.9% (95% CI, 0.6-6.3). The pooled 2-year primary and secondary patency rates were 61.8% (95% CI, 50.0-72.4) and 99.8% (95% CI, 96.2%-100.0%), respectively. Stent type (P = .002) and age (P = .04) were identified as a significant source of heterogeneity for clinical success. In subgroup analysis, the clinical success rate was 85.9% (95% CI, 77.8-91.4) in studies with a majority of covered stents, and 87.6% (95% CI, 74.1-94.6) in studies with a median age of 12 years or older.
CONCLUSIONS: This systematic review and meta-analysis demonstrates that a TIPS is a feasible and safe treatment for pediatric PHT. To improve clinical outcome and patency on the long term, the use of covered stents should be encouraged.